News & Updates

In the first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), adding the anti-PD-1 monoclonal antibody toripalimab to a standard chemotherapy regimen can significantly cut the risk of progression or death without an increase in adverse events, according to the prespecified analysis of the phase III JUPITER-06 trial.

No clinical association exists between predefined genomic risk score and testosterone level in men undergoing radical prostatectomy, according to a study.

New drug applications approved by US FDA as of 16-31 May 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Assessment of the calf circumference (CC) and the triceps-skinfold thickness (TSF) in hospitalized cancer patients is essential in guiding intervention to improve their long-term outcomes, suggests a study.

Inappropriate prescription practices and polypharmacy remain a burden in patients treated with immune checkpoint inhibitors (ICIs), a study has found.